Last reviewed · How we verify
Venetoclax plus RIC
At a glance
| Generic name | Venetoclax plus RIC |
|---|---|
| Sponsor | Xianmin Song, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
- Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation (PHASE2)
- Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia (PHASE2)
- RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR (PHASE4)
- Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies (PHASE2)
- Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venetoclax plus RIC CI brief — competitive landscape report
- Venetoclax plus RIC updates RSS · CI watch RSS
- Xianmin Song, MD portfolio CI